뒤로
AIM ImmunoTech Inc (AIM) 수입
AIM 주가 차트
AIM 수입
AIM ImmunoTech Inc
$0.55
-21.28%
$-0.14
종가: Mar 30, 16:00:00 GMT-4
$0.56
1.85%
$0.01
애프터마켓: Mar 30, 19:22:08 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-17
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
AIM의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
AIM ImmunoTech Inc AIM의 지난 분기 매출 실적은 어땠나요?
AIM ImmunoTech Inc의 매출 추정치는 얼마인가요?
AIM ImmunoTech Inc의 수익 품질 점수는 얼마인가요?
AIM ImmunoTech Inc는 언제 수익을 보고하나요?
AIM ImmunoTech Inc의 예상 수익은 얼마인가요?
AIM ImmunoTech Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.7
시가
$0.7138
일일 범위
$0.53 - $0.7289
52주 범위
$0.5612 - $34.91
거래량
612.8K
평균 거래량
4.7M
배당수익률
--
EPS(TTM)
-24.68
시가총액
$2.3M
AIM란 무엇인가요?
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.